FDA+ roundup: CDER's breakthrough designation requests see steep decline in 2021; Drugmakers call to expand FDA guidance on PD-(L)1 dosing
The once never-ending rise of breakthrough designation requests at the FDA slowed again in 2021, with just over 100 requests coming into the agency, compared …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
